Orphanet Journal of Rare Diseases | Clinical Manifestations and Treatment Outcomes of Cerebral Edema in Adult Patients with Maple Syrup Urine Disease

Recommend:

This article reviews the diverse clinical manifestations of cerebral edema in adult maple syrup urine disease (MSUD) patients during acute metabolic decompensation, highlighting the importance of early recognition and prompt treatment, especially when the multidisciplinary team is unfamiliar with this rare condition.

 

Literature Overview
This article, titled Cerebral edema in maple syrup urine disease: spectrum of clinical presentation and treatment outcomes, published in the Orphanet Journal of Rare Diseases, summarizes 10 cerebral edema episodes across 7 adult MSUD patients admitted to the hospital between 2016 and 2023. The study notes that MSUD is an autosomal recessive neurometabolic disorder caused by dysfunction of the branched-chain α-ketoacid dehydrogenase complex (BCKD), leading to accumulation of branched-chain amino acids (BCAAs: leucine, isoleucine, valine) and their α-ketoacid derivatives (BCKAs), which are neurotoxic. Cerebral edema is a severe complication of acute metabolic decompensation in MSUD that may lead to brain herniation and death. While most literature focuses on pediatric patients, this study focuses on adult cases, revealing the heterogeneity in clinical presentation and the challenges in management.

Background Knowledge
Maple Syrup Urine Disease (MSUD) is a rare metabolic disorder affecting branched-chain amino acid metabolism, with a global incidence of approximately 1 in 185,000. In certain consanguineous populations, such as the Old Order Amish community in the United States and newborns in Saudi Arabia, the incidence is significantly higher. The accumulation of BCAAs and their ketoacid derivatives in the blood and brain interferes with neurotransmitter synthesis, mitochondrial energy metabolism, and brain water homeostasis, ultimately leading to cerebral edema and neurological dysfunction. Current studies mainly focus on pediatric patients, with limited reports on adult cases, resulting in a knowledge gap in clinical management. Additionally, the lack of a clear correlation between leucine levels and the severity of cerebral edema complicates diagnosis and treatment. Therefore, this study fills the gap in the management of acute cerebral edema in adult MSUD patients and emphasizes the importance of multidisciplinary collaboration and early intervention.

 

Enter a gene to explore its associated signaling pathways and known downstream molecules.

Learn More

 

Study Methods and Experiments
This study is a retrospective review analyzing medical records of 7 adult MSUD patients admitted to a tertiary care hospital between 2016 and 2023. It collected clinical presentations, laboratory tests, imaging findings, treatment strategies, and clinical outcomes during acute metabolic crises. All patients exhibited cerebral edema-related symptoms during acute metabolic decompensation, and some were incidentally found to have cerebral edema for non-acute indications, such as MRI evaluation. The study also analyzed the relationship between plasma leucine levels and imaging features of cerebral edema, and assessed the effectiveness of various treatment modalities (e.g., CRRT, hemodialysis, hypertonic saline) in reducing leucine levels and alleviating cerebral edema.

Key Findings and Perspectives

• Adult MSUD patients can develop widespread cerebral edema during acute metabolic crises, but clinical symptoms may be subtle or even absent despite evident imaging findings.
• There is no direct correlation between plasma leucine levels and the severity of cerebral edema. In some patients, cerebral edema worsens despite declining leucine levels, indicating the necessity for integrated assessment using imaging and neurological monitoring.
• Renal replacement therapies (CRRT or hemodialysis) are effective in rapidly lowering leucine levels in adult MSUD patients during acute crises, but should be combined with nutritional support, hypertonic saline, and BCAA-free formulas for comprehensive management.
• Cerebral edema may involve the optic nerve and optic chiasm, leading to papilledema and visual impairment. Fundoscopic examination and OCT assessment are recommended for all MSUD patients.
• Some patients may still progress to tonsillar herniation and die despite timely treatment, suggesting the need for developing non-invasive intracranial pressure monitoring techniques to improve outcomes.

Significance and Future Directions
This study is the first systematic review of cerebral edema in adult MSUD patients, highlighting the unique challenges in managing metabolic decompensation in this population. Future research should focus on elucidating the pathogenesis of cerebral edema, optimizing treatment strategies, and developing more effective non-invasive intracranial pressure monitoring techniques. In addition, management guidelines specific to adult MSUD patients are needed to enhance the ability of multidisciplinary teams in early recognition and intervention.

 

A practical tool to rapidly map DNA or RNA sequences to the genome.

Learn More

 

Conclusion
This article systematically reviews the clinical manifestations and treatment outcomes of cerebral edema in adult MSUD patients during acute metabolic crises. The study finds that despite reductions in plasma leucine levels, some patients still experience worsening cerebral edema, potentially progressing to tonsillar herniation, visual impairment, or death. It underscores the importance of early recognition and multidisciplinary management, particularly in adult patients where clinical presentations are often heterogeneous and non-specific, increasing the risk of misdiagnosis or delayed treatment. Additionally, papilledema and MRI abnormalities are identified as important imaging markers for visual dysfunction, suggesting fundoscopy during acute phases and OCT for optic nerve evaluation. The study calls for the development of adult-specific MSUD management protocols and improved non-invasive intracranial pressure monitoring techniques to enhance outcomes and reduce mortality. These findings offer valuable guidance for clinical practice and rare disease research.

 

Raashda A Sulaiman, Ruqaiah Altassan, Randa Alshammari, Mohamed Al-Owain, and Zuhair Al-Hassnan. Cerebral edema in maple syrup urine disease: spectrum of clinical presentation and treatment outcomes. Orphanet Journal of Rare Diseases.